AI biotech Enveda raises $311M, valuation doubles to $2B
emmanuelvivier · x · 2026-09-25
AI drug-discovery biotech Enveda raised $311M, doubling its valuation to $2B, with three AI-designed treatments now in clinical trials. Also: Gemini's new "Call for Me" feature can call automated phone menus on your behalf with live transcription, coming to Pixel 11.
More from Venture
- Anthropic's July-31×365 Annualized Revenue Method Draw Fire as Son Predicts Labs Must IPO — whurley · 2026-09-25
- Alibaba launches AgentCore agent cloud; Lovable hits $600M annualized revenue — emmanuelvivier · 2026-09-25
- Medical AI coding tools cost Blue Cross insurers $942M via inflated billing — emmanuelvivier · 2026-09-25
- Indie hacker's $10k-in-100-days challenge: CrawlRaven hits $2,744 with 710 users at day 60 — ayushtweetshere · 2026-09-25
- Brookings pegs US AI buildout at $10.3T by 2032, 3.6% of GDP a year — emmanuelvivier · 2026-09-25
- OpenAI rumored to launch $500 ChatGPT Pro Max plan, Kalshi opens a market on it — Kalshi · 2026-09-25